Working… Menu

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03861676
Recruitment Status : Not yet recruiting
First Posted : March 4, 2019
Last Update Posted : April 8, 2021
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:

The Principal Investigator's (PI) working hypothesis is that the PI can utilize the high predictive value of 18F-DCFPyl PSMA to identify clinically significant tumors in patients who will undergo brachytherapy, as well as areas which are uninvolved or contain only clinically insignificant disease.

In the PI's clinical trial, the uninvolved regions (as defined by combined PET-MR-biopsy data) will not be targeted and receive only fall-off dose, which we have shown to be associated with reductions in toxicity.

Condition or disease Intervention/treatment Phase
Prostate Cancer Radiation: Focal brachytherapy with PSMA PET imaging Drug: (18F)DCFPyL Early Phase 1

Detailed Description:

Current conventional prostate cancer (PCa) imaging modalities (computed tomography, bone scan, magnetic resonance imaging, ultrasound) have limited accuracy in the initial staging and for determining prognosis of PCa. Prostate-specific membrane antigen (PSMA) is a cell surface antigen which is highly expressed in PCa and correlates with prognostic factors such as Gleason score. High PSMA expression in prostate tumor has been significantly associated with lethality of disease, allowing specific identification of tumors most in need of treatment. Combined PET and computed tomography (PET-CT) imaging using small molecules targeting PSMA-expressing cells have been developed and tested clinically, and have shown superiority when compared with conventional imaging.

An added advantage of PET compared to MRI is the ability to identify both distant metastatic disease as well as intraprostatic disease with one imaging modality. PSMA-radiotracers have continued to evolve since their initial development, with successive improvements in imaging and diagnostic characteristics. One such second-generation PSMA-binding compound, 18F-DCFPyl, has been developed and characterized at our institution, and offers superior imaging qualities compared to prior PSMA-based radiotracers.

In realization of the toxicity of current therapies, there is substantial interest throughout the urologic oncology community in utilizing focal therapy to mitigate such toxicities. The rationale for focal therapy is based upon the recognition that whole gland treatment is associated with unacceptable toxicity rates, while concurrently it is also realized that patient morbidity and mortality is due to the progression of major foci of high-grade disease, i.e. the index lesion.

Planning studies have shown that focal brachytherapy is feasible and results in significant reductions of dose to critical structures. In a historic cohort of patients treated at Johns Hopkins, the investigators have demonstrated that a modest reduction in dose results in clinically meaningful reductions in urinary toxicity. Al-Qaiseh et al. found that focal plans resulted in >50% reductions in dose to urethra and rectum. However, focal plans were highly sensitive to seed positioning errors, and focal targeting made seed positioning more critical. This highlights the key utility and importance of the investigators' iRUF system (integrated Registered Fluoroscopy and Ultrasound) in delivering focal therapy.

The investigators have developed a system of true dynamic intraoperative dosimetry which utilizes fluoroscopy for seed cloud reconstruction and fusion to transrectal ultrasound imaging. The investigators previously confirmed this method in a pilot trial of 6 patients with encouraging results. Further refinement of the system was followed by a Phase II clinical trial of this integrated platform on a larger group of patients. The investigators confirmed the primary endpoint to compare intraoperative dosimetric predicted values using iRUF method vs standard ultrasound-based seed tracking. The iRUF Phase II cohort had statistically significant improvements in prostate coverage parameters, as well as lower rates of rectal doses exceeding prescribed tolerance limits when compared to a historical group of patients. Importantly, there was no trend toward higher prostate V200 doses, indicating that excellent coverage did not come at the expense of excessive dose within prostate.

This study will test the combination of PSMA-imaging with iRUF dynamic dosimetry to treat prostate cancer with a focal approach.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single-arm
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT and Dynamic Dosimetry With Registered Ultrasound and Fluoroscopy for Localized Prostate Cancer
Estimated Study Start Date : July 2021
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2030

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Focal brachytherapy

Drug: 18F-DCFPyl Other names: PET, PSMA

Procedure: Focal brachytherapy with PSMA PET imaging Other names: Radiotherapy, Radiation, Prostate seed implant, Focal therapy

Radiation: Focal brachytherapy with PSMA PET imaging
Focal brachytherapy with PSMA PET imaging. Focal (partial prostate gland) brachytherapy following 18F-DCFPyl PET/CT radiotracer imaging. Patients will also undergo pre-treatment transperineal mapping biopsy.
Other Names:
  • Prostate seed implant
  • Radiotherapy
  • Radiation
  • Focal therapy

Drug: (18F)DCFPyL
18F-DCFPyl PET/CT scan
Other Name: PSMA, PET

Primary Outcome Measures :
  1. Percent tumor coverage [ Time Frame: Post-implant Day 30 ]

    Percent coverage of the combined PET-MR based tumor volume achieved when using iRUF intraoperative dosimetry.

    PET-MR tumor volume D90 will be defined on pre-treatment PET-MR fusion, and dose from seeds will be calculated on post-implant MR/CT (Day ~30); the two volumes will be co-registered to determine tumor volume coverage.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adenocarcinoma of the prostate
  • Performance Status < 2
  • Clinical stages (not radiographic stage) T1c - T2a, Nx or N0, Mx or M0
  • Gleason 6-7 cancer
  • Prostate volume < 60 cc (if MRI and TRUS have conflicting values, then MRI value will be utilized)
  • International Prostate symptom score (IPSS) 20 or less
  • Ability to undergo DCF-Pyl PSMA PET as part of pretreatment staging
  • Signed study-specific consent form prior to registration

Exclusion Criteria:

  • Prior history of pelvic radiation therapy
  • Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow up.
  • Implanted device or apparatus which obstruct visibility of the implanted sources on fluoroscopy
  • Metallic implants, claustrophobia not amenable to medication, or known contraindications to undergoing MR scanning
  • History of other malignancy diagnosed within the past 3 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03861676

Layout table for location contacts
Contact: Daniel Song, MD (410) 502-5875
Contact: Dana Kaplin (410) 614-3950

Layout table for location information
United States, Maryland
SKCCC at Johns Hopkins
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Daniel Song, MD Johns Hopkins University
Layout table for additonal information
Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Identifier: NCT03861676    
Other Study ID Numbers: J1889
IRB00173561 ( Other Identifier: JHM IRB )
R01CA151395 ( U.S. NIH Grant/Contract )
First Posted: March 4, 2019    Key Record Dates
Last Update Posted: April 8, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:
focal therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases